Lausanne (Switzerland): ADC Therapeutics has received the Salus Partner Excellence in HealthTech Award at the Convergence in Oncology Summit held here on September 12-13.
The award recognises ADC Therapeutics’ excellence in execution and the rapid development of its product pipeline in the field of targeted cancer therapy.
ADC Therapeutics SA is a clinical-stage oncology-focused biotechnology company pioneering the development of “highly potent and targeted antibody” drug conjugates for patients suffering from haematological malignancies and solid tumours.
The Salus Partners Excellence in HealthTech Award celebrates excellence in entrepreneurship and innovation in healthcare. The award is presented each year to the CEO of an emerging company with significant potential for disruptive improvement in patient care.
Upon receiving the award Dr Chris Martin, Co-founder & CEO of ADC Therapeutics, said: “We are very happy and honoured to receive the 2019 Salus Excellence in HealthTech Award. It is a much appreciated recognition of our success in the development of our unique next-generation product pipeline to treat as many patients as possible worldwide.”
“ADC Therapeutics joins a prestigious group of companies recognised by the Salus Partners Excellence in HealthTech Award. They are a great example of the flourishing innovation in the field of oncology here in Switzerland,” said Dr Brian Hashemi, Co-Founder of the Convergence in Oncology Summit and Managing Partner of the investment firm Salus Partners SA in Lausanne, Switzerland.
The Convergence in Oncology Summit is an international annual assembly of industry leaders, entrepreneurs, and investors dedicated to exploring synergies that accelerate the development of the most promising solutions for improved patient outcomes.